Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency

Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1117-9. doi: 10.1097/01.meg.0000231749.60889.f7.


Bosentan has lately been described as a successful therapeutic agent for portopulmonary hypertension consecutive to child A cirrhosis. This is the first report of the effect of this substance with advanced liver cirrhosis (child C) and renal insufficiency. Low doses of bosentan (initially twice 31.25 mg/day and then 62.5 mg/day) increased cardiac output and allowed correction of renal insufficiency; it allowed one to stop the requirement of oxygen and not only improved the 6-min walking test by more than 400 m, but also decreased the severity of the liver cirrhosis to child B stadium. This suggests that patients, who would be excluded from a liver transplantation program because of their portopulmonary hypertension, could profit from a careful therapy with bosentan.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antihypertensive Agents / therapeutic use*
  • Bosentan
  • Humans
  • Hypertension, Portal / drug therapy*
  • Hypertension, Portal / etiology
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / etiology
  • Liver Cirrhosis / complications*
  • Male
  • Renal Insufficiency / complications
  • Sulfonamides / therapeutic use*
  • Treatment Outcome


  • Antihypertensive Agents
  • Sulfonamides
  • Bosentan